CRISPR Therapeutics Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
CRISPR Therapeutics AG (CRSP) IPO Opens Up 7%
October 19, 2016 10:37 AM EDTToday's IPO for CRISPR Therapeutics AG (Nasdaq: CRSP) opened for trading at $15 after pricing its initial public offering of 4,000,000 common shares at a public offering price of $14.00 per share.
Citigroup, Piper Jaffray and Barclays are acting as joint book-running managers for the offering.... More
